Press Release

SAJA Pharmaceuticals in Saudi Arabia Selects IQVIA's OCE Solution

Mar 09, 2021

[March 9, 2021] IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that SAJA Pharmaceuticals has selected IQVIA Technologies’ Orchestrated Customer Engagement (OCE) platform as its CRM solution.

“SAJA Pharmaceuticals is proud and glad to be part of the OCE platform’s growing family,” said SAJA Sales Force Effectiveness Manager. “This service agreement adds to the business solutions range that we are implementing with the help of IQVIA in the field of advanced business analytics and tech solutions. We are sure that the implementation of OCE, as a service segment leader, will help SAJA to enhance the customer experience, strengthen customers relationships and performance.”

IQVIA Technologies’ OCE for advanced customer engagement breaks down silos by seamlessly connecting sales, account management, marketing, and other functions to enhance the customer experience, strengthen relationships and drive performance. The OCE SaaS-based platform is built on best-in-class technologies such as Salesforce, Mulesoft, Heroku and others. With unique capabilities, such as predictive analytics and machine learning, OCE provides an intuitive user experience, AI-enabled recommendations, fluid integration with other applications to deliver smarter, coordinated engagements with healthcare professionals.

“We are excited to have SAJA on our Orchestrated Customer Engagement Platform,” said Ravi Akella, Sr. Director, Commercial Technologies for IQVIA . “With COVID-19, customer engagement models are evolving and OCE supports SAJA’s ambition to transform customer engagement and improve customers’ trust and loyalty.”

SAJA Pharmaceuticals joins 140 other life sciences customers that have selected IQVIA OCE’s innovative solutions to address market momentum and the need for innovative platforms to advance customer engagement.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

About SAJA Pharmaceuticals

SAJA is a joint venture between the premier Saudi healthcare company FMTI Holding and two of the leading Japanese Pharmaceutical companies which are Daiichi Sankyo Company and Astellas Pharma Inc.

Contact Us